By Associate Professor Anthony Michael Joshua

Conference Posters

Joshua AM; Vukovic B; Braude I; Hussein S; Zielenska M; Srigley JR; Evans AJ; Squire JA, 2007, 'Telomere length analysis of high-grade prostatic intraepithelial neoplasia (HPIN) and adjacent stroma predicts outcome in prostate cancer and provides evidence of field carcinogenesis', CA, San Diego, Vol. 20, pp. 154A - 154A, presented at 96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, CA, San Diego, 24 March 2007 - 30 March 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000244922401120&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Prasad M; Fleshner N; Finelli A; Evans A; Sweet J; Squire J; Zielenska M, 2006, 'Detection of novel variant TMPRSS2/ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer.', GA, Atlanta, Vol. 24, pp. 548S - 548S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009403484&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Joshua AM; Vukovic B; Braude I; Evans A; Srigley J; Squire JA, 2006, 'Telomere dysfunction in prostatic carcinogenesis.', GA, Atlanta, Vol. 24, pp. 546S - 546S, presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, GA, Atlanta, 02 June 2006 - 06 June 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000239009403477&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Joshua AM; Mei C; Braude I; Collins T; Vukovic B; Srigley JR; Evans AJ; Squire JA, 2006, 'Developing techniques in high-throughput telomere analysis for the study of prostatic carcinogenesis', GA, Atlanta, Vol. 19, pp. 329A - 330A, presented at 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, GA, Atlanta, 11 February 2006 - 17 February 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000234094502480&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Joshua AM; Mei C; Braude I; Collins T; Vukovic B; Srigley JR; Evans AJ; Squire JA, 2006, 'Developing techniques in high-throughput telomere analysis for the study of prostatic carcinogenesis', GA, Atlanta, Vol. 86, pp. 329A - 330A, presented at 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, GA, Atlanta, 11 February 2006 - 17 February 2006, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000234207602385&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Joshua AM; Nordman I; Venkatawaran R; Stockler M; Boyer M; Clarke S, 2005, 'Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC).', FL, Orlando, Vol. 23, pp. 431S - 431S, presented at 41st Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 13 May 2005 - 17 May 2005, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000230326602542&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Presentations

Montgomery B; Joshua A; Gleave M; Fleshner N; Bubley G; True L; Tretiakova M; Wu K; Novotny W; Peterson A; Amelsberg A; Taplin ME, 2015, 'A randomized, open-label, phase 2 study of enzalutamide as neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer', presented at European Cancer Congress 2015 / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), AUSTRIA, Vienna, 25 September 2015 - 29 September 2015, http://dx.doi.org/10.1016/S0959-8049(16)31323-5

Daud A; Ribas A; Robert C; Hodi FS; Wolchok JD; Joshua AM; Hwu W-J; Weber JS; Gangadhar TC; Joseph RW; Dronca RS; Patnaik A; Zarour HM; Kefford R; Lindia JA; Li XN; Ebbinghaus S; Kang SP; Hamid O, 2015, 'Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.', presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036901915&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Chacon-Fajardo D; Porazinski S; Man J; Yim H; El-Omar E; Joshua A; Pajic M, 2024, 'Abstract A029: Re-purposing non-oncology agent itraconazole to target the dynamic cellular ecosystem of pancreatic cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. A029 - A029, http://dx.doi.org/10.1158/1538-7445.panca2023-a029

Porazinski S; Man J; Chacon-Fajardo D; Yim H; El-Omar E; Joshua A; Pajic M, 2024, 'Abstract C017: The anti-fungal itraconazole improves immunotherapy efficacy in pancreatic ductal adenocarcinoma by reversing the immune-suppressive tumor microenvironment', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. C017 - C017, http://dx.doi.org/10.1158/1538-7445.panca2023-c017

Handel E; Leslie C; Ardolino L; Di Ciaccio PR; Grimison P; Ben T; Honeyball F; Lewin J; Viiala N; Murphy C; Milliken S; Bilmon I; Marx G; Gangatharan S; Hamid A; Zhang A; Hamad N; McCarthy L; Joshua AM; Barnet M, 2022, 'Descriptive analysis of bleomycin induced lung injury in a cohort of patients with germ cell tumours and Hodgkin's lymphoma', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000879941200033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Aggarwal N; Parmar J; Zdanska O; Yousif J; Hurwitz J; Handel E; Prawira A; Joshua A; Cosman R; Liu JJ, 2022, 'Impact of Covid-19 on early phase clinical trials recruitment and treatment in a major metropolitan phase 1 unit', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 33 - 34, http://dx.doi.org/10.1111/ajco.13856

Zdanska O; Zdansky P; Liu J; Joshua A; Stanners M; Rogers C, 2022, 'Patient experiences of prolonged living with cancer during early phase trial treatment', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 147 - 147, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Parmar J; Aggarwal N; Zdanska O; Yousif J; Hurwitz J; Handel E; Rodrigues A; Prawira A; Joshua A; Cosman R; Liu J, 2022, 'Telehealth maintains access to early phase clinical trials during the Covid-19 pandemic', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 154 - 155, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500233&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Jones RH; Pinato DJ; Joshua A; Forster MD; Morton C; Aboud K; Liu JJ; Fulgenzi C; Kefas J; Edmondson S; Main NJ; Paull JRA; Fairley JK; Spicer J, 2022, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1186 - S1187, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000866211601660&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Pathmanandavel S; Stockler M; Crumbaker M; Sharma S; Ayers M; Niman R; Wilson P; Martin A; Hickey A; Joshua A; Nguyen A, 2022, 'Evaluation of Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, Vol. 49, pp. S54 - S54, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000857046600103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Buteau J; Martin A; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee S; Azad A; McJannett M; Stockler MR; Williams S; Davis ID; Hofman MS, 2022, 'PSMA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial of [Lu-177]Lu-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603)', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, Vol. 49, pp. S55 - S55, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000857046600105&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chin V; Arora H; Senabouth A; Hernandez JA; McCloy R; Simes J; Boyer M; Hogg P; Young J; Joshua A; Brown B; Watkins N; Powell J, 2022, 'Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, Vol. 17, pp. S608 - S608, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000858678101548&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Allen IA; Russell A; Jackson KJ; Peters T; Gibson G; Joshua AM; Goodnow CC; Burnett DL; Barnet MB, 2022, 'Abstract 665: Correlation between a CTLA-4 single nucleotide polymorphism and high response to anti-PD1/PDL1 immunotherapy in advanced non small cell lung cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. 665 - 665, http://dx.doi.org/10.1158/1538-7445.am2022-665

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Kumar AR; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of Lu-177-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301433&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sacco JJ; Orloff MM; Patel SP; Conway M; Lim L-A; Fog LS; Sia D; McKenzie J; Mckay D; O'day R; Isaacs T; Shoushtari AN; Sullivan RJ; Kin S; Gwadry-Sridhar FH; Joshua AM; Carvajal RD, 2022, 'Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680305166&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

Hamid A; Hofman MS; Bressel M; Emmett L; Joshua AM; Spain LA; Horvath L; Crumbaker M; Pasam A; Callahan J; Tubbs A; Fernandez L; Wenstrup RJ; Kong G; Lewin JH; Tran B; Azad A; Schonhoft JD; Hicks RJ; Sandhu S, 2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sandhu S; Joshua AM; Emmett L; Spain LA; Horvath L; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Dhiantravan N; Akhurst TJ; Ravi Kumar A; Alipour R; Scalzo M; Williams S; Hicks R; Hofman MS, 2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

Conduit C; Kichenadasse G; Harris CA; Gurney H; Ferguson T; Parnis F; Goh JC; Morris MF; Underhill C; Pook DW; Davis ID; Roncolato F; Harrison ML; Begbie S; Joshua AM; Link E; Hovey EJ; Gedye C, 2022, 'Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 4537 - 4537, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4537

Conduit C; Kichenadasse G; Harris CA; Gurney H; Ferguson T; Parnis F; Goh JC; Morris MF; Underhill C; Pook DW; Davis ID; Roncolato F; Harrison ML; Begbie S; Joshua AM; Link E; Hovey EJ; Gedye C, 2022, 'Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab plus nivolumab in advanced nonclear cell renal cell carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301357&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5000 - 5000, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5000

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Williams S; Martin AJ; Davis ID, 2022, 'TheraP: Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301419&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pham J; Star P; Phan K; Loh Y; Joshua AM; Smith A, 2022, 'BRAF inhibition and the spectrum of Granulomatous Reactions', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY, Vol. 63, pp. 106 - 106, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000788396100260&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pook DW; Geynisman DM; Carles J; De Braud FG; Joshua AM; Perez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve MA; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund S; Harris A; Huang K-C; Sutaria DS; Gurney H, 2022, 'A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 95 - 95, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.095

Emmett L; Subramaniam S; Martin AJ; Zhang AY; Yip S; Crumbaker M; Rana N; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; Weickhardt AJ; Goh JC; Ng S; Voskoboynik M; McJannett MM; Stockler MR; Davis ID, 2022, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS205

De Bono JS; Joshua AM; Shore ND; Kramer G; Li XT; Poehlein CH; Schloss C; Yu EY, 2022, 'KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS218 - TPS218, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.tps218

Kramer G; Shore ND; Joshua AM; Li XT; Poehlein CH; Schloss C; De Bono JS; Yu EY, 2022, 'KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS215 - TPS215, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.tps215

Shore ND; De Bono JS; Kramer G; Joshua AM; Li XT; Poehlein CH; Schloss C; Yu EY, 2022, 'KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab + vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS204 - TPS204, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.tps204

Mak B; Lin H-M; Mahon KL; Joshua AM; Stockler MR; Gurney H; Parnis F; Zhang AY; Scheinberg T; Wittert G; Butler L; Hoy A; Meikle P; Horvath L, 2022, 'Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.154

Ferrario C; Piulats JM; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PCC; Berry WR; Emmenegger U; Mourey L; Mar N; Appleman LJ; Joshua AM; Conter HJ; Li XT; Schloss C; Poehlein CH; De Bono JS; Yu EY, 2022, 'Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 118 - 118, http://dx.doi.org/10.1200/jco.2022.40.6_suppl.118

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu SK; Joshua AM; Zhang AY; Francis RJ; Scott AM; Azad A; McJannett MM; Stockler MR; Williams S; Davis ID; Hofman MS, 2022, 'PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.010

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166

Fleshner NE; Hansen AR; Chin J; Winquist E; Van der Kwast T; Lajkosz K; Kenk M; Berlin D; Veloso R; Sridhar SS; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta AR; Joshua AM, 2022, 'Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.224

Todenhoefer T; Piulats JM; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Fong PCC; Berry WR; Emmenegger U; Mourey L; Mar N; Appleman LJ; Joshua AM; Conter HJ; Li XT; Schloss C; Poehlein CH; De Bono JS; Yu EY, 2022, 'KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)-naive patients with metastatic castration-resistant prostate cancer (mCRPC)', in EUROPEAN UROLOGY, ELSEVIER, Vol. 81, pp. S789 - S790, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000812320400519&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin H-M; Mak B; Huynh K; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Stockler MR; Briscoe K; Marx GM; Du P; Yu J; Jia S; Joshua AM; Azad AA; Butler LM; Meikle PJ; Horvath LG, 2021, 'Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S666 - S667, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1148

Mak B; Lin H-M; Kwan EM; Fettke H; Tran B; Davis ID; Mahon KL; Stockler MR; Briscoe K; Marx GM; Kohli M; Tan W; Huynh K; Du P; Yu J; Jia S; Joshua AM; Azad AA; Meikle PJ; Horvath LG, 2021, 'Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S642 - S643, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1109

Sandhu SK; Joshua AM; Emmett L; Spain L; Horvath LG; Crumbaker M; Anton A; Wallace R; Pasam A; Bressel M; Cassidy E; Banks P; Kumar AR; Alipour R; Akhurst T; Kong G; Davis ID; Williams S; Hicks R; Hofman M, 2021, 'PRINCE: Interim analysis of the phase Ib study of Lu-177-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2021, '177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.6

Lau B; Crumbaker M; Yam AOW; Marastoni S; Luckhurst M; O'Grady A; Wouters B; Joshua AM, 2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.114

Emmett L; Subramaniam S; Zhang AY; Martin AJ; Yip S; Crumbaker M; Rana N; Ford K; Langford A; Francis RJ; Hofman MS; Joshua AM; Sandhu SK; Azad A; Gedye C; McJannett MM; Stockler MR; Davis ID, 2021, 'ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS177

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103

Gedye C; Pook DW; Krieger LEM; Harris CA; Goh JC; Kichenadasse G; Gurney H; Underhill C; Parnis F; Joshua AM; Ferguson T; Roncolato F; Harrison ML; Begbie S; Morris MF; Hovey EJ; George M; Prithviraj P; Liow ECH; Davis ID, 2021, 'UNISON - nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1-Nivolumab monotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.325

Azad A; Dhiantravan N; Emmett L; Joshua AM; Vela I; Pattison DA; Francis RJ; Williams S; Sandhu SK; Davis ID; Neha N; Bressel M; Murphy DG; Hofman MS, 2021, 'UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS180

Joshua AM; Prawira A; Thavaneswaran S; Cosman R; Lee CK; Sjoquist KM; Simes J; Thomas DM; Espinoza D; Sebastian L; Ballinger ML; Hague W; Chinchen S; Collignon E; Kansara M; Palacios T; Grady J; Barker H; Thornton K, 2020, 'A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors: A sub-study of the cancer molecular screening and therapeutics (MoST) program.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368301329&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page